

GLAXOSMITHKLINE PLC
Form 6-K
August 06, 2009

FORM 6-K

**SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549**

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For period ending August 2009

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

--

Notifiable Share Interest in Vernalis plc ("Vernalis")

GlaxoSmithKline plc ("GSK") announces that on 5 August 2009, SmithKline Beecham Corporation, a wholly owned subsidiary of GSK, agreed to subscribe for 2,040,542 ordinary shares in Vernalis (representing 3.39% of the enlarged share capital of Vernalis) for an aggregate subscription price of £1.77 million (\$3 million). Vernalis plc is a development stage pharmaceutical company whose shares are traded on the London Stock Exchange..

The subscription is being made in connection with a collaboration, option and license agreement reached between the two companies, relating to a Vernalis research programme in oncology. An up-front payment in cash of \$3 million was also made to Vernalis plc on signing of the agreement.

S M Bicknell

Company Secretary

5 August 2009

Enquiries:

UK Media enquiries:	Philip Thomson	(020) 8047 5502
	David Outhwaite	(020) 8047 5502
	Stephen Rea	(020) 8047 5502
	Alexandra Harrison	(020) 8047 5502

US Media enquiries:	Nancy Pekarek	(919) 483 2839
	Mary Anne Rhyne	(919) 483 2839
	Kevin Colgan	(919) 483 2839
	Lisa Behrens	(919) 483 2839

European Analyst/Investor enquiries:	David Mawdsley	(020) 8047 5564
	Sally Ferguson	(020) 8047 5543
	Gary Davies	(020) 8047 5503

US Analyst/ Investor enquiries:	Tom Curry	(215) 751 5419
	Jen Hill Baxter	(215) 751 7002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: August 6 2009

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc